Search for: "Mylan Pharmaceuticals"
Results 101 - 120
of 738
Sort by Relevance
|
Sort by Date
19 Oct 2020, 4:15 am
Mylan ca [read post]
5 Oct 2020, 10:25 am
Mylan Pharmaceuticals Inc., No. 19-1451; Arthrex, Inc. v. [read post]
5 Oct 2020, 2:00 am
Settle in with the Chat Français for some French carb loading of delicious, fresh patent decisions from the first half of 2020Finding it difficult to keep up with an ever-changing world in the midst of a health, environmental, social and political crisis, while keeping up with patent law? [read post]
27 Sep 2020, 6:36 pm
Mylan Pharmaceuticals Inc., No. 19-1451; Arthrex, Inc. v. [read post]
20 Aug 2020, 9:59 pm
By Kevin E. [read post]
19 Aug 2020, 12:40 am
This Kat has sufficiency (of mice) objectionsWelcome to the latest IPKat roundup, which should especially cheer fans of patent news and views.PatentsKodak's most recent endeavours, by way of an announced pivot to generic pharmaceutical manufacturing thanks to a US government COVID-response loan, swiftly followed by an insider trading investigation which put the loan on hold, drew comment from PermaKat Neil Wilkof.In news from Australia, GuestKat Rose Hughes reported on the confirmation… [read post]
13 Aug 2020, 12:56 am
Data is necessary to overcome the strict sufficiency requirements for patentability of pharmaceutical and biotech inventions in Europe and elsewhere. [read post]
31 Jul 2020, 9:40 am
For the reasons described below, we affirm.The matters at issue:In 2016, Takeda sued Mylan Pharmaceuticals Inc. forpatent infringement based on Mylan’s recently submittedAbbreviated New Drug Application (“ANDA”) for a genericversion of Takeda’s Colcrys® product, which is a brandedversion of the drug colchicine. [read post]
1 Jul 2020, 4:32 pm
Jane Lambert Court of Appeal (Lords Justices Floyd, Males and Arnold) Neurim Pharmaceuticals (1991) Ltd and another v Generics UK Ltd (t/a Mylan) and another [2020] EWCA Civ 793 (24 June 2020) This was an appeal by the claimants, Neurim Pharmaceuticals (1991) Ltd ("Neurim") and its exclusive licensee Flynn Pharma Ltd ("Flynn"), against Mr Justice Marcus Smith's refusal in Neurim [read post]
1 Jul 2020, 1:15 am
Mylan, upholding Marcus Smith J.'s decision to deny an interim injunction against a generic company which launched at risk.Fellow GuestKat Rose Hughes reported on the judgment of the UK Supreme Court in Regeneron v Kymab, which found Regeneron's patents to be invalid for insufficiency, overturning the Court of Appeal decision and confirming the UK's strong sufficiency requirement.Trade MarksPermaKat Neil J. [read post]
26 Jun 2020, 2:53 am
On the ball as always, Joost told me that the appeal in Neurim Pharmaceuticals v. [read post]
25 Jun 2020, 3:49 am
A key part of the basis for arguing that damages will not be an adequate remedy in any pharmaceutical case is often the price spiral that will occur if multiple generics launch. [read post]
21 Jun 2020, 8:15 pm
Eli Lilly & Co. and "Ariad Pharmaceuticals Inc. v. [read post]
10 Jun 2020, 8:10 am
The patent is licensed to Flynn Pharmaceuticals. [read post]
4 Jun 2020, 12:51 pm
Jane Lambert Patents Court (Mr Justice Msrcus Smith) Neurim Pharmaceuticals (1991) Ltd and another v Generics UK Ltd (t/a Mylan) and another [2020] EWHC 1362 (Pat) (3 June 2020) This was an application by Neurim Pharmaceuticals (1991) Ltd. [read post]
21 Apr 2020, 6:30 am
Mylan Pharmaceuticals, Inc., the Federal Circuit reversed the District Court of New Jersey’s grant of summary judgement in favor of Valeant that claim 8 of U.S. [read post]
21 Apr 2020, 6:00 am
Mylan Pharmaceuticals, Inc., the Federal Circuit reversed the District Court of New Jersey’s grant of summary judgement in favor of Valeant that claim 8 of U.S. [read post]
10 Apr 2020, 4:15 am
In Valeant Pharmaceuticals v. [read post]
10 Apr 2020, 4:15 am
In Valeant Pharmaceuticals v. [read post]
8 Apr 2020, 9:59 pm
Mylan Pharmaceuticals Inc. [read post]
